secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K/A
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001213900-25-093983
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix files Melinta acquisition financials; Melinta 2024 revenue $120M, net loss $4.7M
--------------------------------------------------------------------------------

- Melinta 2024 total revenue $119.97M (product $106.3M) vs $105.6M in 2023; net loss narrowed to $4.7M from $36.0M.
- Cash and equivalents $49.8M at Dec 31, 2024; total assets $177.6M, notes payable $84.9M.
- CorMedix acquired Melinta on Aug 29, 2025 for undisclosed terms; Melinta markets seven anti-infective brands including BAXDELA, VABOMERE, ORBACTIV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025093983/0001213900-25-093983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025093983/ea0258874-8ka1_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-093983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer